<SEC-DOCUMENT>0001213900-25-073669.txt : 20250808
<SEC-HEADER>0001213900-25-073669.hdr.sgml : 20250808
<ACCEPTANCE-DATETIME>20250808161506
ACCESSION NUMBER:		0001213900-25-073669
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250808
FILED AS OF DATE:		20250808
DATE AS OF CHANGE:		20250808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASCENTAGE PHARMA GROUP INTERNATIONAL
		CENTRAL INDEX KEY:			0002023311
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42484
		FILM NUMBER:		251198588

	BUSINESS ADDRESS:	
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		STATE:			F4
		ZIP:			00000
		BUSINESS PHONE:		86 512 8555 7777

	MAIL ADDRESS:	
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		STATE:			F4
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea025244901-6k_ascentage.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Washington,
D.C. 20549 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Form 6-K
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>under the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the month of <B>August 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Commission File Number: 001-42484</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Translation of Registrant&rsquo;s name into English)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>68 Xinqing Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Suzhou Industrial Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Suzhou, Jiangsu</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form 20-F &#9746; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 8, 2025, Ascentage Pharma
Group International posted an announcement on the Hong Kong Stock Exchange entitled, &ldquo;Notice of Board Meeting&rdquo;. A copy of
the announcement is furnished as Exhibit 99.1 to this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INDEX TO EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top; width: 7%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Number</B>&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 92%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Title</B></FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: blue"><FONT STYLE="color: Black"><A HREF="ea025244901ex99-1_ascentage.htm">Announcement dated August 8, 2025</A></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 8, 2025</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Dajun Yang</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Dajun Yang</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea025244901ex99-1_ascentage.htm
<DESCRIPTION>ANNOUNCEMENT DATED AUGUST 8, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><I>Hong
Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,
make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising
from or in reliance upon the whole or any part of the contents of this announcement.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.9pt 7.7pt 0 6.05pt; text-align: justify; text-indent: -0.05pt; color: #231F20"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="image_003.jpg" ALT="" STYLE="width: 253px; height: 80px"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 5.8pt 10.7pt 0 11.1pt; text-align: center; color: #231F20">ASCENTAGE
PHARMA GROUP INTERNATIONAL</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 10.7pt 0 14.65pt; text-align: center; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 10.7pt 0 14.65pt; text-align: center; color: #231F20">&#20126;&#30427;&#37291;&#34277;&#38598;&#22296;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 10.7pt 0 9pt; text-align: center; color: #231F20"><I>(Incorporated in the
Cayman Islands with limited liability)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.6pt 0 0 0.3pt; text-align: center; color: #231F20"><B>(Stock Code: 6855)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 13.3pt 10.7pt 0 11.05pt; text-align: center; color: #231F20"><B>NOTICE OF
BOARD MEETING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 13.3pt 10.7pt 0 11.05pt; text-align: center; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
board of directors (the &ldquo;<B>Board</B>&rdquo;) of Ascentage Pharma Group International (the &ldquo;<B>Company</B>&rdquo;, together
with its subsidiaries, collectively the &ldquo;<B>Group</B>&rdquo;) hereby announces that a meeting of the Board will be held on Wednesday,
August 20, 2025, for the purpose of, among other things, considering and, if appropriate, approving the unaudited interim results of
the Group for the six months ended June 30, 2025 and its publication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 10.85pt 0 294.6pt; text-align: center; color: #231F20">By order of the Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.2pt 10.7pt 0 294.6pt; text-align: center; color: #231F20"><B>Ascentage Pharma
Group International Dr. Yang Dajun</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.2pt 13.3pt 0 294.6pt; text-align: center; color: #231F20"><I>Chairman and
Executive Director</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Suzhou,
People&rsquo;s Republic of China, August 8, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><I>As
at the date of this announcement, the Board comprises Dr. Yang Dajun as chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu
Simon Dazhong as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky, Ms. Marina S. Bozilenko, Dr. Debra
Yu and Marc E. Lippman, MD as independent non-executive Directors.</I></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !0 /T# 2(  A$! Q$!_\0
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M/V5SO7_&N8E@UCPE=@AFA#'AE.Z.3^GY\T^6G5^%Z^?]?YDNI5H_&M/+^O\
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DH[>WBM8$AMXUCB0;511@ 5)7+5GSR<CJIPY(J(4445F6?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
